Newamsterdam Pharma Company N.V. (NAMS)
NASDAQ:NAMS
Want to see NAMS full AI Analyst Report?
Top Page
NewAmsterdam Pharma Company
(NASDAQ:NAMS)
Select Model
Select Model
Rating:56Neutral
Price Target:
$33.00
▼(-4.84% Downside)
Action:Reiterated
Date:05/09/26
The score is held down primarily by weak financial performance (deep losses and substantial cash burn despite a strong balance sheet). Offsetting factors include constructive technical momentum and a positive product/progress update, while valuation is constrained by the negative P/E and lack of dividend data.
Positive Factors
Very conservative balance sheet / minimal debt
Minimal debt and a large equity base materially reduce refinancing and interest-rate risk for a clinical-stage biotech. This solvency gives management time to advance Phase 3/approval activities and supports pre-launch investments without immediate forced capital raises, strengthening strategic optionality.
Negative Factors
Substantial cash burn
Sustained negative operating and free cash flow near -$142M TTM creates dependence on external financing to fund trials, regulatory submissions and commercialization. Ongoing high burn increases dilution risk and imposes execution pressure on management to secure non-dilutive or capital markets funding before key milestones.
Read all positive and negative factors
Positive Factors
Negative Factors
Very conservative balance sheet / minimal debt
Minimal debt and a large equity base materially reduce refinancing and interest-rate risk for a clinical-stage biotech. This solvency gives management time to advance Phase 3/approval activities and supports pre-launch investments without immediate forced capital raises, strengthening strategic optionality.
Read all positive factors
NewAmsterdam Pharma Company (NAMS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$3.94B
Dividend YieldN/A
Average Volume (3M)1.43M
Price to Earnings (P/E)―
Beta (1Y)1.29
Revenue Growth-52.13%
EPS Growth3.91%
CountryUS
Employees68
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.81
Shares Outstanding116,903,980
10 Day Avg. Volume1,320,123
30 Day Avg. Volume1,425,589
Financial Highlights & Ratios
PEG Ratio0.62
Price to Book (P/B)5.87
Price to Sales (P/S)178.34
P/FCF Ratio-27.11
Enterprise Value/Market Cap0.88
Enterprise Value/Revenue154.21
Enterprise Value/Gross Profit158.13
Enterprise Value/Ebitda-15.01
Forecast
1Y Price Target
$47.86Price Target Upside38.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-1.83
Revenue Forecast (FY)$29.28M
NewAmsterdam Pharma Company Business Overview & Revenue Model
Company Description
NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets t...
How the Company Makes Money
As a clinical-stage biopharmaceutical company, NewAmsterdam Pharma’s ability to generate recurring commercial revenue is limited until it obtains regulatory approvals and launches products. Publicly available sources do not provide sufficient, con...
NewAmsterdam Pharma Company Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
82
Very Positive
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 22.57M | 22.50M | 45.56M | 14.09M | 102.69M | 0.00 |
| Gross Profit | 22.01M | 22.44M | 45.56M | 14.09M | 102.69M | 0.00 |
| EBITDA | -231.81M | -242.32M | -241.49M | -176.86M | -22.34M | -41.37M |
| Net Income | -212.73M | -203.82M | -241.60M | -176.94M | -22.63M | -41.78M |
Balance Sheet | ||||||
| Total Assets | 732.64M | 769.28M | 864.62M | 347.10M | 478.50M | 67.99M |
| Cash, Cash Equivalents and Short-Term Investments | 636.11M | 636.24M | 834.19M | 340.45M | 467.73M | 60.38M |
| Total Debt | 23.00K | 202.00K | 448.00K | 60.00K | 126.00K | 186.51K |
| Total Liabilities | 67.42M | 85.85M | 107.12M | 58.70M | 48.43M | 11.36M |
| Stockholders Equity | 665.22M | 683.43M | 757.50M | 288.39M | 430.07M | 56.63M |
Cash Flow | ||||||
| Free Cash Flow | -142.19M | -148.03M | -159.24M | -141.24M | 10.44M | -29.54M |
| Operating Cash Flow | -141.92M | -147.78M | -158.56M | -141.22M | 10.66M | -29.51M |
| Investing Cash Flow | -189.28M | -174.92M | -62.85M | -24.00K | -221.00K | -24.00K |
| Financing Cash Flow | 34.07M | 29.52M | 659.51M | 8.91M | 391.90M | 84.70M |
NewAmsterdam Pharma Company Technical Analysis
Negative
34.68
Price Trends
33.16
Negative
33.00
Negative
32.89
Negative
Market Momentum
0.38
Positive
41.49
Neutral
24.79
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NAMS, the sentiment is Negative. The current price of 34.68 is below the 20-day moving average (MA) of 35.06, above the 50-day MA of 33.16, and above the 200-day MA of 32.89, indicating a bearish trend. The MACD of 0.38 indicates Positive momentum. The RSI at 41.49 is Neutral, neither overbought nor oversold. The STOCH value of 24.79 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NAMS.
NewAmsterdam Pharma Company Risk Analysis
NewAmsterdam Pharma Company disclosed 92 risk factors in its most recent earnings report. NewAmsterdam Pharma Company reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
NewAmsterdam Pharma Company Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | $3.72B | 50.72 | 13.26% | ― | 56.71% | ― | |
62 Neutral | $5.29B | -12.18 | -49.23% | ― | -100.00% | -46.29% | |
62 Neutral | $6.84B | -13.24 | -68.16% | ― | ― | -1.22% | |
56 Neutral | $3.94B | -18.10 | -29.80% | ― | -52.13% | 3.91% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | $3.80B | -7.65 | -71.31% | ― | ― | -259.98% |
* Healthcare Sector Average
NAMS
NewAmsterdam Pharma Company
31.79
13.10
70.09%
VKTX
Viking Therapeutics
31.27
4.66
17.51%
XENE
Xenon
53.41
22.69
73.86%
KNSA
Kiniksa Pharmaceuticals
48.43
19.32
66.37%
IMVT
Immunovant
32.86
17.42
112.82%
NewAmsterdam Pharma Company Corporate Events
Executive/Board Changes
NewAmsterdam Pharma Announces Chief Accounting Officer Transition Agreement
Neutral
Apr 24, 2026
On April 20, 2026, NewAmsterdam Pharma Company N.V. and Chief Accounting Officer Louise Kooij agreed that her employment would end effective August 31, 2026, and on April 24, 2026, they executed a separation agreement detailing her departure terms...
Business Operations and StrategyFinancial DisclosuresProduct-Related Announcements
NewAmsterdam Highlights Obicetrapib Progress in Investor Presentation
Positive
Mar 2, 2026
On March 2, 2026, NewAmsterdam Pharma posted an updated corporate investor presentation detailing recent clinical, commercial, and financial progress around its lead candidate obicetrapib. The company highlighted Phase 2 and Phase 3 data indicatin...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.